GlassScriptPhysician profile
Malathi V Ellis
NPI 1861509275
$4,092.95
in general payments reported to CMS, 2019-2025
29 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $1,076 · 2021: $1,491 · 2022: $124 · 2023: $699 · 2024: $141 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.98 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $947.67 | 2021 | |
| Allergan, INC. | $707.67 | 2020 | |
| Abbvie INC. | $504.44 | 2019-2023 | |
| Dexcom, INC. | $339.29 | 2023-2025 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $181.85 | 2019-2025 | Slynd |
| Pacira Pharmaceuticals Incorporated | $175.48 | 2020-2023 | Exparel |
| Astellas Pharma US INC | $141.60 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $134.13 | 2023 | Myfembree |
| Coopersurgical, INC. | $124.25 | 2020 | |
| Vivus LLC | $120.29 | 2025 | Qsymia |
| Gynesonics, INC. | $103.19 | 2021 | |
| Organon LLC | $87.66 | 2021-2024 | Jada System |
| Vertical Pharmaceuticals, LLC | $62.12 | 2019 | |
| Therapeuticsmd, INC. | $59.34 | 2019-2021 | |
| Pfizer INC. | $54.78 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $44.83 | 2023 | Intrarosa |
| Bayer Healthcare Pharmaceuticals INC. | $40.90 | 2022 | |
| Boston Scientific Corporation | $32.24 | 2023 | Bodyguardian |
| Abbott Laboratories | $31.80 | 2019-2020 | |
| Hologic Sales and Service, LLC | $29.57 | 2019-2022 | |
| Axonics, INC. | $29.18 | 2023 | Axonics |
| Avion Pharmaceuticals | $28.77 | 2019 | |
| Daiichi Sankyo INC. | $26.30 | 2019-2020 | |
| Minerva Surgical, INC | $25.98 | 2024 | |
| Agile Therapeutics, INC. | $16.19 | 2021 | |
| Evofem Biosciences, INC. | $15.45 | 2021 | |
| Sage Therapeutics, LLC | $14.29 | 2021 | |
| Lupin INC. | $13.69 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malathi Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.